Dennis Slamon

Dennis J. Slamon
Dennis J. Slamon
Born	August 6, 1948; New Castle, Pennsylvania
Alma mater	Washington & Jefferson College (B.A.); University of Chicago (Ph.D. cell biology, M.D. (1975))
Occupation(s)	oncologist, professor
Awards	Gairdner Foundation International Award (2007); Scheele Award (2009); The Sjöberg Prize (2019)

Dennis Joseph Slamon (born August 6, 1948), is an American oncologist and chief of the division of Hematology-Oncology at UCLA. He is best known for his work identifying the HER2/neu oncogene that is amplified in 25–33% of breast cancer patients and the resulting treatment trastuzumab.

He currently serves as director of Clinical/Translational Research at UCLA's Jonsson Comprehensive Cancer Center, and as director of the Revlon/UCLA Women's Cancer Research Program at JCCC. He is a professor of medicine, chief of the Division of Hematology/Oncology and executive vice chair for research for UCLA's Department of Medicine. Slamon also serves as director of the medical advisory board for the National Colorectal Cancer Research Alliance, a fund-raising organization that promotes advances in colorectal cancer.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.